Published in Law and Health Weekly, July 16th, 2005
Ethics approval for this trial was announced on March 7, 2005.
The trial is designed to validate two primary endpoints for Melanotan for fair-skinned Caucasians who are the expected target patients for this therapy. The trial aims to establish a "protection" rating for Melanotan similar to that used in sunscreens.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly